Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

Autor:	Amer M. Zeidan, Kiyoshi Ando, Odile Rauzy, Mehmet Turgut, Ming-Chung Wang, Roberto Cairoli, Hsin-An Hou, Yok-Lam Kwong, Montserrat Arnan Sangerman, Stef Meers, Vinod A. Pullarkat, Valeria Santini, Kamel Malek, Flavia Kiertsman, Jiaying Lyu, Pedro Marques Ramos, Pierre Fenaux, Yasushi Miyazaki, Uwe Platzbecker
Přispěvatelé:	Zeidan, A, Ando, K, Rauzy, O, Turgut, M, Wang, M, Cairoli, R, Hou, H, Kwong, Y, Sangerman, M, Meers, S, Pullarkat, V, Santini, V, Malek, K, Kiertsman, F, Lyu, J, Ramos, P, Fenaux, P, Miyazaki, Y, Platzbecker, U
Jazyk:	angličtina
Rok vydání:	2022
Předmět:	Sabatolimab MDS MED/15 - MALATTIE DEL SANGUE Immunology Cell Biology Hematology Biochemistry
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23c141ab9d0ac7d7d5923b5c0a6f03c6 https://hdl.handle.net/10281/411282 Zobrazit plný text záznamu